TransMedics CEO raises guidance to $595M after stock jumps 15% - here's why
Key Points
- TransMedics exceeded earnings expectations by 100% in Q2, bo...
When your business involves keeping human organs alive outside the human body, beating earnings expectations by 100% seems almost quaint. TransMedics just delivered exactly that kind of performance, sending their stock up 15% faster than a heart surgeon running to the OR.
The medical device company reported Q2 earnings of $0.92 per share - double what analysts expected - alongside a 38% year-over-year revenue jump. CEO Waleed Hassanein was so confident he bumped up full-year sales guidance from $575 million to $595 million, because apparently nothing says "we've got this" like raising your t...
While we have taken every measure to build an AI pipeline that generates credible and accuracte news, we still encourage you to conduct your own research before making investment decisions. InsAIght's content should not be considered professional financial or trading advice.